Stock Events

Stock Events

Search...

Shield Therapeutics

€0.02

21

+€0+0% Friday 06:02

Statistics

Day High

0.02

Day Low

0.02

52W High

-

52W Low

-

Volume

0

Avg. Volume

-

Mkt Cap

14.49M

P/E Ratio

-

Dividend Yield

-

Dividend

-

Earnings

30JunConfirmed

Q3 2019

Q4 2019

Q1 2020

Q2 2020

Q3 2020

Q4 2020

Q1 2021

-0.03

-0.01

0

0.02

Expected EPS

0

Actual EPS

-0.0275

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1JS.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Amgen develops treatments in areas similar to Shield Therapeutics, including anemia which directly competes with Shield's Feraccru/Iron product.

AbbVie competes in the pharmaceutical space with products that could serve as alternatives to treatments offered by Shield Therapeutics, especially in gastrointestinal and chronic conditions.

AstraZeneca operates in similar therapeutic areas as Shield, including treatments for anemia and other conditions that Shield's products address.

Johnson & Johnson

Johnson & Johnson, through its pharmaceutical division Janssen, offers a wide range of products that compete across the board with Shield's portfolio, including anemia and chronic disease treatments.

GlaxoSmithKline has a broad portfolio that includes treatments for conditions like anemia, competing with Shield's main product offerings.

Pfizer has a diverse drug portfolio that includes treatments in areas competing with Shield Therapeutics, particularly in chronic diseases and conditions treated by Shield's products.

Novartis offers a wide range of pharmaceutical products, including those for anemia and chronic conditions, directly competing with Shield Therapeutics' market.

Bristol-Myers Squibb

Bristol Myers Squibb competes in the global pharmaceutical market with a focus on serious diseases, including areas that overlap with Shield Therapeutics' focus areas.

Merck operates in various therapeutic areas, including those that compete with Shield Therapeutics, offering alternative treatments for conditions like anemia.

Sanofi produces a range of pharmaceutical products that compete with Shield Therapeutics, especially in the chronic disease treatment space.

About

Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.

Show more...

CEO

Mr. Gregory P. Madison

Employees

73

Country

GB

ISIN

GB00BYV81293

WKN

000A2AE98

Listings